Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
30.44
+0.43 (1.43%)
At close: Mar 30, 2026, 4:00 PM EDT
30.50
+0.06 (0.20%)
After-hours: Mar 30, 2026, 7:36 PM EDT

Company Description

Veracyte, Inc. operates as a diagnostics company in the United States and internationally.

The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.

It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.

Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Veracyte, Inc.
Veracyte logo
CountryUnited States
Founded2006
IPO DateOct 30, 2013
IndustryDiagnostics & Research
SectorHealthcare
Employees755
CEOMarc Stapley

Contact Details

Address:
6000 Shoreline Court, Suite 300
South San Francisco, California 94080
United States
Phone650 243 6300
Websiteveracyte.com

Stock Details

Ticker SymbolVCYT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001384101
CUSIP Number92337F107
ISIN NumberUS92337F1075
Employer ID20-5455398
SIC Code8071

Key Executives

NamePosition
Marc A. StapleyChief Executive Officer and Director
Dr. Phillip G. Febbo M.D.Chief Scientific and Medical Officer
Annie McGuireExecutive Vice President, General Counsel and Chief People Officer
Dr. John Leite Ph.D.Global Chief Commercial Officer
Dr. Keith Gligorich Ph.D.Senior Vice President of Global Operations
Jonathan WygantVice President and Chief Accounting Officer
Dr. Kevin Richard Haas Ph.D.Chief Development and Technology Officer
Steven FrenchSenior Vice President and Chief Information Officer
Karen PossematoSenior Vice President of Corporate Marketing, Communications and Commercial Operations
Corinne DananSenior Vice President

Latest SEC Filings

DateTypeTitle
Mar 27, 2026SCHEDULE 13G/AFiling
Mar 16, 20268-KCurrent Report
Mar 4, 2026144Filing
Mar 4, 2026144Filing
Mar 4, 2026144Filing
Mar 4, 2026144Filing
Mar 2, 2026144Filing
Feb 26, 202610-KAnnual Report
Feb 25, 20268-KCurrent Report
Feb 5, 2026SCHEDULE 13G/AFiling